Blog

An Evidence-Based Look at New IBS-C Constipation Treatment Options Irritable Bowel Syndrome with constipation (IBS-C) is defined by chronic abdominal pa…

Introduction A 2026 review synthesizing mechanistic and clinical research offers a new perspective on managing constipation-predominant irritable bowel …

Rifaximin Shows Most Consistent Efficacy in SIBO and IBS Overlap, Systematic Review Finds Gastroenterologists Qadir Shah and Jonathan Soldera analyzed 5…

Persistent Poor Diet Blocks Exercise and Inulin FMT Benefits in Obesity Study Researchers from Japan and Australia reported that fecal microbiota transp…

Managing IBS-C: A New Review Maps How Natural Products Target Underlying Causes Irritable bowel syndrome with constipation (IBS-C) is a complex disorder…

Rifaximin Shows Most Consistent Efficacy for IBS-D and SIBO with 16.7% Adverse Event Rate A 2026 systematic review of 55 studies concluded that the anti…

Introduction Small intestinal bacterial overgrowth (SIBO) is not an isolated problem; it is often a symptom of impaired intestinal housekeeping

An Evidence-Based Path to Managing IBS-C Constipation Irritable bowel syndrome with constipation (IBS-C) is a complex disorder where chronic abdominal p…

According to a 2026 systematic review published in World Journal of Methodology, rifaximin demonstrated the most consistent efficacy for treating irrita…

Beyond Fiber: A Pathophysiology-Driven Approach to IBS-C Management Irritable bowel syndrome with constipation, or IBS-C, is a complex disorder affectin…

Rifaximin Is the Most Consistently Effective Antibiotic for SIBO and IBS-D, According to a 2026 Review A systematic review published in World Journal of…

A New Path for IBS-C: How Natural Products and Meal Timing Target Root Causes Irritable bowel syndrome with constipation affects millions, often reducin…